FDA Grants Orphan Drug Status to Soin Therapeutics for Low Dose Naltrexone (LDN) to Treat Complex Regional Pain Syndrome (CRPS)

DAYTON, Ohio, Sept. 9, 2021 /PRNewswire/ -- Soin Therapeutics, a pharmaceutical company based in Dayton, OH, was granted orphan drug status from the FDA for low dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS). FDA Grants Orphan Drug Status to Soin Therapeutics for Low...

from PR Newswire: https://ift.tt/3jXrTJ6